Devices & Diagnostics

In India, Medtronic enters hemodialysis field with $25 million investment

Medtronic (MDT) has signed a deal with Apollo Hospitals Enterprise to develop a new hemodialysis system to help patients with end-stage renal disease (ESRD). The medical devices company will cover the technology, Apollo the “clinical insight.” This collaboration marks the first instance Medtronic will use a full India-based R&D team. Medtronic said it will develop […]

Medtronic (MDT) has signed a deal with Apollo Hospitals Enterprise to develop a new hemodialysis system to help patients with end-stage renal disease (ESRD). The medical devices company will cover the technology, Apollo the “clinical insight.” This collaboration marks the first instance Medtronic will use a full India-based R&D team.

Medtronic said it will develop and manufacture key components of a hemodialysis system that will help these patients who need renal replacement therapy, while improving affordability and access. Dialysis, the company claims, is the second-best treatment for ESRD, when RRT isn’t an option. As much as 10 percent of the Indian population has chronic kidney disease. And, a whopping 90 percent of patients who receive dialysis in India receive hemodialysis.

The product, which represents a $25 million investment, will commercially launch in 2016.

“In the case of hemodialysis, both the cost and lack of mobility of current systems have made broader access to dialysis treatment difficult and expensive.  Our goal is to build a unique, internally developed system that will be portable, will lower costs, and will be more efficient in its use of water and other critical features than existing dialysis systems.  Our collaboration with Apollo allows us to further tailor our system to best meet the needs of patients and physicians in India and will leverage Apollo’s deep expertise and reach in treating ESRD patients,” Omar Ishrak,  Medtronic chairman and CEO, said in a release.